Law360, New York (May 11, 2011, 5:26 PM ET) -- A Texas federal judge ruled Monday that a former Amgen Inc. employee failed to fully support claims in a qui tam False Claims Act suit accusing dialysis provider DaVita Inc. of receiving kickbacks in the form of educational grants from the drugmaker.
The relator, Ivey Woodard, claimed that DaVita violated the FCA by saying it was in compliance with the anti-kickback statute while it was accepting educational grants from Amgen in exchange for purchasing its blood drug Epogen, or EPO, a drug that stimulates red blood...
Judge Snips DaVita Kickback Claims In FCA Suit
To view the full article, take a free trial now.
